Jung Kwon Kim, Sung Han Kim, Mi Kyung Song, Jungnam Joo, Seong Il Seo, Cheol Kwak, Chang Wook Jeong, Cheryn Song, Eu Chang Hwang, Ill Young Seo, Hakmin Lee, Sung-Hoo Hong, Jae Young Park, Jinsoo Chung, Korean Renal Cell Carcinoma Study Group
Cancer Res Treat. 2019;51(2):758-768. Published online September 7, 2018
Purpose
The International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) and the Memorial Sloan Kettering Cancer Center (MSKCC) risk models were developed predominantly with clear cell renal cell carcinoma (RCC). Accordingly, whether these two models could be applied to metastatic non-clear cell RCC (mNCCRCC) as well has not been well-known and was investigated herein.
Materials and Methods
From the Korean metastatic RCC registry, a total of 156 patients (8.1%) with mNCCRCC among the entire cohort of 1,922 patients were analyzed. Both models were applied to predict first-line progression-free survival (PFS), total PFS, and cancer-specific survival (CSS).
Results
The median first-line PFS, total PFS, and CSS were 5, 6, and 24 months, respectively. The IMDC risk model reliably discriminated three risk groups to predict survival: the median firstline PFS, total PFS, and CSS for the favorable, intermediate, and poor risk groups were 9, 5, and, 2 months (p=0.001); 14, 7, and 2 months (p < 0.001); and 41, 21, and 8 months (p < 0.001), all respectively. The MSKCC risk model also reliably differentiated three risk groups: 9, 5, and, 2 months (p=0.005); 10, 7, and 3 months (p=0.002); and 50, 21, and 8 months (p < 0.001), also all respectively. The concordance indices were 0.632 with the IMDC model and 0.643 with the MSKCC model for first-line PFS: 0.748 and 0.655 for CSS.
Conclusion
The current IMDC and MSKCC risk models reliably predict first-line PFS, total PFS, and CSS in mNCCRCC.
Citations
Citations to this article as recorded by
Advances in non‐clear cell renal cell carcinoma management: From heterogeneous biology to treatment options Nathaniel R. Wilson, Yusuf Acikgoz, Elshad Hasanov International Journal of Cancer.2024; 154(6): 947. CrossRef
Survival pattern of metastatic renal cell carcinoma patients according to WHO/ISUP grade: a long-term multi-institutional study Joongwon Choi, Seokhwan Bang, Jungyo Suh, Chang Il Choi, Wan Song, Hyeong Dong Yuk, Chan Ho Lee, Minyong Kang, Seol Ho Choo, Jung Kwon Kim, Hyung Ho Lee, Jung Ki Jo, Eu Chang Hwang, Chang Wook Jeong, Young Hwii Ko, Jae Young Park, Cheryn Song, Seong Il Se Scientific Reports.2024;[Epub] CrossRef
Prognostic Factors and Treatment Outcomes in Renal Cell Carcinoma: A Comprehensive Analysis Ömer Faruk ELÇİÇEK, Mehmet KÜÇÜKÖNER Namık Kemal Tıp Dergisi.2024; : 217. CrossRef
High Sensitivity Circulating Tumor-DNA Assays in Renal Cell Carcinoma–Are we there yet? Fady Sidhom, Shefali Patel, Arpita Desai, Arnab Basu Clinical Genitourinary Cancer.2024; 22(6): 102235. CrossRef
Machine learning based prediction for oncologic outcomes of renal cell carcinoma after surgery using Korean Renal Cell Carcinoma (KORCC) database Jung Kwon Kim, Sangchul Lee, Sung Kyu Hong, Cheol Kwak, Chang Wook Jeong, Seok Ho Kang, Sung-Hoo Hong, Yong-June Kim, Jinsoo Chung, Eu Chang Hwang, Tae Gyun Kwon, Seok-Soo Byun, Yu Jin Jung, Junghyun Lim, Jiyeon Kim, Hyeju Oh Scientific Reports.2023;[Epub] CrossRef
Targeted Literature Review of Outcomes to Initial Systemic Therapy for Advanced/Metastatic Non-Clear Cell Renal Cell Carcinoma in Observational Studies Shawna R. Calhoun, Manish Sharma, Chung-Han Lee Kidney Cancer.2023; 7(1): 123. CrossRef
A retrospective single-centered, comprehensive targeted genetic sequencing analysis of prognostic survival using tissues from Korean patients with metastatic renal cell carcinoma after targeted therapy Sung Han Kim, Jongkeun Park, Weon Seo Park, Dongwan Hong, Jinsoo Chung Investigative and Clinical Urology.2022; 63(6): 602. CrossRef
Overall survival in patients with metastatic renal cell carcinoma in Russia, Kazakhstan, and Belarus: a report from the RENSUR3 registry Ilya Tsimafeyeu, Oxana Shatkovskaya, Sergei Krasny, Nurzhan Nurgaliev, Ilya Varlamov, Vladislav Petkau, Sufia Safina, Ruslan Zukov, Mikhail Mazhbich, Galina Statsenko, Sergey Varlamov, Olga Novikova, Igor Zaitsev, Pavel Moiseyev, Alexander Rolevich, Alesy Cancer Reports.2021;[Epub] CrossRef
The prognostic effect of immunoscore in patients with clear cell renal cell carcinoma: preliminary results Ismail Selvi, Umut Demirci, Nazan Bozdogan, Halil Basar International Urology and Nephrology.2020; 52(1): 21. CrossRef
Life expectancy in patients with metastatic renal cell carcinoma in the Russian Federation: results of the RENSUR3 multicenter registry study I. V. Tsimafeyeu, I. S. Varlamov, V. V. Petkau, S. Z. Safina, R. A. Zukov, M. S. Mazhbich, G. B. Statsenko, S. A. Varlamov, I. V. Zaitsev, O. Yu. Novikova, S. А. Krasny, N. S. Nurgaliyev, I. L. Popova, L. Yu. Vladimirova Malignant tumours.2019; 9(2): 45. CrossRef
Purpose
The purpose of this study was to evaluate the association of androgen deprivation therapy (ADT) with cognitive dysfunction.
Materials and Methods
Using the National Health Insurance Service database of the entire Korean adult prostate cancer population (n=236,391), data on ADT and cognitive dysfunction between 2008 and 2015 were analyzed. We excluded patients previously diagnosed with cognitive dysfunction, dementia, or a cerebral event history. We tested the effect of ADT on the risk of cognitive dysfunction using propensity score–matched Cox proportional hazards regression models and Kaplan-Meier survival analysis. Our final cohort comprised of 35,401 individuals with prostate cancer, including 24,567 men (70.6%) who underwent ADT.
Results
During a mean follow-up period of 4.1 years, 4,741 patients were newly diagnosed with cognitive dysfunction. A statistically significant association was found between ADT and the risk of cognitive dysfunction (hazard ratio, 1.169; p=0.002). Meanwhile, age (≥ 70 years), diabetes, hypertension, cardiovascular history, and peripheral vascular disease were identified as factors that contribute to the increased risk of cognitive dysfunction. In contrast, the use of statins and aspirin was associated with a lower risk of cognitive dysfunction. Kaplan-Meier analysis demonstrated that patients aged 70 years or older who underwent ADT had the lowest cumulative probability of remaining cognitive dysfunction-free (log-rank p < 0.001).
Conclusion
Our results revealed an association between the use of ADT for the treatment of prostate cancer and an increased risk of cognitive dysfunction in a nationwide population-based study. This finding should be further evaluated in prospective studies.
Citations
Citations to this article as recorded by
Unraveling the bidirectional link between cancer and dementia and the impact of cancer therapies on dementia risk: A systematic review and meta‐analysis Liwei Ma, Edwin C. K. Tan, Benjamin Goudey, Liang Jin, Yijun Pan Alzheimer's & Dementia.2025;[Epub] CrossRef
Androgen deprivation therapy for prostate cancer and neurocognitive disorders: a systematic review and meta-analysis David E. Hinojosa-Gonzalez, Affan Zafar, Gal Saffati, Shane Kronstedt, Dimitar V. Zlatev, Mohit Khera Prostate Cancer and Prostatic Diseases.2024; 27(3): 507. CrossRef
Antineoplastics for treating Alzheimer's disease and dementia: Evidence from preclinical and observational studies Viswanath Das, John H. Miller, Charanraj Goud Alladi, Narendran Annadurai, Juan Bautista De Sanctis, Lenka Hrubá, Marián Hajdúch Medicinal Research Reviews.2024; 44(5): 2078. CrossRef
Cognitive effects of long‐term androgen deprivation therapy in older men with prostate cancer Denise Pergolizzi, Kathleen R. Flaherty, Rebecca M. Saracino, James C. Root, Elizabeth Schofield, Caroline Cassidy, Vani Katheria, Sunita K. Patel, William Dale, Christian J. Nelson Psycho-Oncology.2024;[Epub] CrossRef
Psychosocial Factors Associated with Cognitive Function in Prostate Cancer Survivors on Hormonal Treatments: A Systematic Review Lorna Pembroke, Kerry A. Sherman, Heather Francis, Haryana M. Dhillon, Howard Gurney, David Gillatt Neuropsychology Review.2024;[Epub] CrossRef
Androgen deprivation therapy exacerbates Alzheimer’s-associated cognitive decline via increased brain immune cell infiltration Chao Zhang, Mae Aida, Shalini Saggu, Haiyan Yu, Lianna Zhou, Hasibur Rehman, Kai Jiao, Runhua Liu, Lizhong Wang, Qin Wang Science Advances.2024;[Epub] CrossRef
Risks associated with cognitive function and management strategies in the clinical use of ADT: a systematic review from clinical and preclinical studies Meng-fan Cui, Li-ming Chen, Cindy Jiang, Bing-zhe Ma, Fu-wen Yuan, Chen Zhao, Shi-min Liu Supportive Care in Cancer.2024;[Epub] CrossRef
Urogeriatrisches Denken am Beispiel der antiandrogenen Therapie des Prostatakarzinoms A. Wiedemann, A. Manseck, J. Stein, M. Fröhner, C. Fiebig, A. Piotrowski, R. Kirschner-Hermanns Die Urologie.2024; 63(9): 867. CrossRef
Untangling the role of tau in sex hormone responsive cancers: lessons learnt from Alzheimer's disease Rachel M. Barker, Alfie Chambers, Patrick G. Kehoe, Edward Rowe, Claire M. Perks Clinical Science.2024; 138(21): 1357. CrossRef
A Systematic Review on the Potential Acceleration of Neurocognitive Aging in Older Cancer Survivors Charlotte Kerstens, Hans P. M. W. Wildiers, Gwen Schroyen, Mercedes Almela, Ruth E. Mark, Maarten Lambrecht, Sabine Deprez, Charlotte Sleurs Cancers.2023; 15(4): 1215. CrossRef
Comparison of Cerebral Blood Flow in Regions Relevant to Cognition After Enzalutamide, Darolutamide, and Placebo in Healthy Volunteers: A Randomized Crossover Trial Steven C. R. Williams, Ndaba Mazibuko, Owen O’Daly, Christian Zurth, Fiona Patrick, Christian Kappeler, Iris Kuss, Patricia E. Cole Targeted Oncology.2023; 18(3): 403. CrossRef
Does ADT Influence the Risk of Suicidal Ideation among US Veteran Prostate Cancer Patients Pre-Exposed to PTSD? Smit Brahmbhatt, Herta H. Chao, Shiv Verma, Sanjay Gupta Cancers.2023; 15(10): 2739. CrossRef
Androgen deprivation therapy and risk of cognitive dysfunction in men with prostate cancer: is there a possible link? Myungsun Shim, Woo Jin Bang, Cheol Young Oh, Yong Seong Lee, Jin Seon Cho Prostate International.2022; 10(1): 68. CrossRef
Impact of Testosterone on Alzheimer’s Disease Vittorio Emanuele Bianchi The World Journal of Men's Health.2022; 40(2): 243. CrossRef
Androgen‐targeting therapeutics mitigate the adverse effect of GnRH agonist on the risk of neurodegenerative disease in men treated for prostate cancer Gregory L. Branigan, Georgina Torrandell‐Haro, Maira Soto, Edward P. Gelmann, Francesca Vitali, Kathleen E. Rodgers, Roberta Diaz Brinton Cancer Medicine.2022; 11(13): 2687. CrossRef
Assessment and Management of Cognitive Function in Patients with Prostate Cancer Treated with Second-Generation Androgen Receptor Pathway Inhibitors Jeffrey S. Wefel, Charles J. Ryan, Julie Van, James C. Jackson, Alicia K. Morgans CNS Drugs.2022; 36(5): 419. CrossRef
The Insignificant Correlation between Androgen Deprivation Therapy and Incidence of Dementia Using an Extension Survival Cox Hazard Model and Propensity-Score Matching Analysis in a Retrospective, Population-Based Prostate Cancer Registry Young Ae Kim, Su-Hyun Kim, Jae Young Joung, Min Soo Yang, Joung Hwan Back, Sung Han Kim Cancers.2022; 14(11): 2705. CrossRef
Treatment of non-metastatic castration-resistant prostate cancer: facing age-related comorbidities and drug–drug interactions David Conde-Estévez, Iván Henríquez, Jesús Muñoz-Rodríguez, Alejo Rodriguez-Vida Expert Opinion on Drug Metabolism & Toxicology.2022; 18(9): 601. CrossRef
Testosterone and Alzheimer’s disease K. O. Kuznetsov, R. R. Khaidarova, R. H. Khabibullina, E. S. Stytsenko, V. I. Filosofova, I. R. Nuriakhmetova, E. M. Hisameeva, G. S. Vazhorov, F. R. Khaibullin, E. A. Ivanova, K. V. Gorbatova Problems of Endocrinology.2022; 68(5): 97. CrossRef
Quantifying observational evidence for risk of dementia following androgen deprivation therapy for prostate cancer: an updated systematic review and meta-analysis Haiying Cui, Yao Wang, Fei Li, Guangyu He, Zongmiao Jiang, Xiaokun Gang, Guixia Wang Prostate Cancer and Prostatic Diseases.2021; 24(1): 15. CrossRef
Risk of Cognitive Effects in Comorbid Patients With Prostate Cancer Treated With Androgen Receptor Inhibitors Alicia K. Morgans, Joseph Renzulli, Kara Olivier, Neal D. Shore Clinical Genitourinary Cancer.2021; 19(5): 467.e1. CrossRef
Association between Androgen Deprivation Therapy and Risk of Dementia in Men with Prostate Cancer Jui-Ming Liu, Chin-Yao Shen, Wallis C. Y. Lau, Shih-Chieh Shao, Kenneth K. C. Man, Ren-Jun Hsu, Chun-Te Wu, Edward Chia-Cheng Lai Cancers.2021; 13(15): 3861. CrossRef
Prostate cancer treatment and the relationship of androgen deprivation therapy to cognitive function A. B. Reiss, U. Saeedullah, D. J. Grossfeld, A. D. Glass, A. Pinkhasov, A. E. Katz Clinical and Translational Oncology.2021; 24(5): 733. CrossRef
Biomarkers to Evaluate Androgen Deprivation Therapy for Prostate Cancer and Risk of Alzheimer’s Disease and Neurodegeneration: Old Drugs, New Concerns Vérane Achard, Kelly Ceyzériat, Benjamin B. Tournier, Giovanni B. Frisoni, Valentina Garibotto, Thomas Zilli Frontiers in Oncology.2021;[Epub] CrossRef
Does androgen deprivation impact associations between cognition and strength, fitness and function in community-dwelling men with prostate cancer? A cross-sectional study Niamh L Mundell, Patrick J Owen, Jack Dalla Via, Helen Macpherson, Robin M Daly, Steve F Fraser BMJ Open.2021; 11(12): e058478. CrossRef
Antiaging Therapies, Cognitive Impairment, and Dementia Devin Wahl, Rozalyn M Anderson, David G Le Couteur, Rafael de Cabo The Journals of Gerontology: Series A.2020; 75(9): 1643. CrossRef
A review of prostate cancer treatment impact on the CNS and cognitive function Charles Ryan, Jeffrey S. Wefel, Alicia K. Morgans Prostate Cancer and Prostatic Diseases.2020; 23(2): 207. CrossRef
Diagnostic accuracy of administrative database for bile duct cancer by ICD-10 code in a tertiary institute in Korea Young-Jae Hwang, Seon Mee Park, Soomin Ahn, Jongchan Lee, Young Soo Park, Nayoung Kim Hepatobiliary & Pancreatic Diseases International.2020; 19(6): 575. CrossRef
WITHDRAWN: The Changes of ADC Value, DCE-MRI Parameters and Their Influence on Neuropsychology in Prostate Cancer Patients after Endocrine Therapy Based on Magnetic Resonance Imaging Yang Lu, Shang Ge, Yan Liu, Gengji Bai Neuroscience Letters.2020; : 135221. CrossRef
Neuropsychiatric Impact of Androgen Deprivation Therapy in Patients with Prostate Cancer: Current Evidence and Recommendations for the Clinician Aisha L. Siebert, Leiszle Lapping-Carr, Alicia K. Morgans European Urology Focus.2020; 6(6): 1170. CrossRef
An Updated Review: Androgens and Cognitive Impairment in Older Men Zhonglin Cai, Hongjun Li Frontiers in Endocrinology.2020;[Epub] CrossRef
Risk of dementia and Parkinson’s disease in patients treated with androgen deprivation therapy using gonadotropin-releasing hormone agonist for prostate cancer: A nationwide population-based cohort study Myungsun Shim, Woo Jin Bang, Cheol Young Oh, Yong Seong Lee, Seong Soo Jeon, Hanjong Ahn, Young-Su Ju, Jin Seon Cho, Gianluigi Forloni PLOS ONE.2020; 15(12): e0244660. CrossRef
Androgen deprivation therapy for prostate cancer and risk of dementia David Robinson, Hans Garmo, Mieke Van Hemelrijck, Jan‐Erik Damber, Ola Bratt, Lars Holmberg, Lars‐Olof Wahlund, Pär Stattin, Jan Adolfsson BJU International.2019; 124(1): 87. CrossRef
Investigational luteinizing hormone releasing hormone (LHRH) agonists and other hormonal agents in early stage clinical trials for prostate cancer Nirmish Singla, Rashed A. Ghandour, Ganesh V. Raj Expert Opinion on Investigational Drugs.2019; 28(3): 249. CrossRef
Cognitive functioning in thyroid cancer survivors: a systematic review and meta-analysis Omar Saeed, Lori J. Bernstein, Rouhi Fazelzad, Mary Samuels, Lynn A. Burmeister, Lehana Thabane, Shereen Ezzat, David P. Goldstein, Jennifer Jones, Anna M. Sawka Journal of Cancer Survivorship.2019; 13(2): 231. CrossRef
Is androgen deprivation therapy associated with cerebral infarction in patients with prostate cancer? A Korean nationwide population‐based propensity score matching study Bum Sik Tae, Byeong Jo Jeon, Hoon Choi, Jae Hyun Bae, Jae Young Park Cancer Medicine.2019; 8(9): 4475. CrossRef
Jung Suk Kim, Jae Young Park, Sang Chul Chae, Moo Chul Shin, Moon Seob Bae, Ji Woong Son, Kwan Young Kim, Tae Kyung Kang, Ki Soo Park, Chang Ho Kim, Sin Kam, Tae Hoon Jung
PURPOSE Lung cancer is now one of the most frequently diagnosed cancers in the world and its incidence has been increasing also in Korea. In several recent studies, the indidence of adenocarcinoma and female/male ratio have been reported to be increasing. The aim of this study is to investigate the changing trends in sex and age distribution, the histologic type and location (peripheral or central) of tumors in lung cancer. MATERIALS AND METHODS We performed the retrospective review of histopathology and clinical information of 1409 patients diagnosed as baving primary lung cancer, except non-epithelial tumors and undetermined histologic types, at Kyungpook National University Hospital from January 1988 to December 1996. RESULTS Male to female ratio was 4.6; 1. The peak incidence of age group was 7th decade (40.3%) with mean age of 61.5.
Percentage of smokers in patients with lung cancer was 84.3%. Total number of patients with lung cancer has increased recently. However, the annual female/male ratio was nearly constant during the study period. Peripheral tumors, which were found in 20.6% of patients with lung cancer in 1988, increased to 33.5% in 1996 and this trend was more prominent in squamous cell carcinoma than in adenocarcinoma. Squamous cell carcinoma was the most common histologic type (62.0%), followed by adenocarcinoma (19.2%), small cell carcinoma (14.2%), large cell carcinoma (4.6%) in order. There was a predominance of squamous cell carcinoma (67.9%) in males and of adenocarcinoma (46.6%) in females.
There has been a significant shift in the histology pattern with an increase in the percentage of adenocarcinoma. The incidence of adenocarcinoma was more than doubled from 7.5% in 1988 to 25.8% in 1996. CONCLUSION These findings suggest that the epidemiology of lung cancer is changing.
PURPOSE In recent years there has been a considerable increase in the use of chemotherapy as an adjuvant to surgery, radical radiotherapy and in addition to best supportive care. However, the value of chemotherapy in improving survival is still unclear, despite more than 50 randomised trials addressing this question in the different stages of disease. This study was done to evaluate Korean doctors' personal management preference and their beliefs about prognosis in non-small celllung cancer(NSCLC). MATERIALS AND METHODS A mail survey of Korean respirologists, thoracic surgeons, radiation oncologists, and medical oncologists was performed. Four cases of NSCLC were described and respondents were asked to give their treatment recommendations and to estimate the prognosis in each case. RESULTS After a complete resection for stage II NSCLC, 27% recommended no adjuvant treatment, 36% recommended radiotherapy, 18% recommended chemotherapy, and 19% recommended both radiotherapy and chemotherapy. After a complete resection for stage IIIA(N2) NSCLC, the vast majority of respondents recommended adjuvant therapy. For an asymptomatic patient with stage IIIB NSCLC, 5% recommended supportive care, 24% recommended radiotherapy, 16% recommended chemotherapy, and 54% recommended chemotherapy combined with radiotherapy. For a patient with stage IV NSCLC, 76% recommended chemotherapy with or without palliative radiotherapy. Doctors' treatment preference was significantly different by their speciliaty in a case with stage II, IIIA(N2), or IV NSCLC. Most respondents believed that chemotherapy would increase survival in NSCLC. Doctors' beliefs about the efficacy of treatment were strongly associated with their treatment recommendations. CONCLUSION Korean doctors generally preferred relatively aggressive management although their personal preferences varied widely. Team approach is important in deciding the treatment modality because doctors' treatment preference is different by their speciality.